United States Health

Eli Lilly (NYSE:LLY) reported an indirect comparison suggesting that Foundayo 17.2 mg produced greater weight loss and A1C reduction than oral semaglutide 25 mg in adults with type 2 diabetes.

Psyence BioMed (NASDAQ:PBM) announced that its Texas subsidiary signed a binding term sheet with PsyLabs for proposed exclusive U.S. ibogaine rights.

Adicet Bio (NASDAQ:ACET) reported Phase 1 safety and efficacy data for prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus with or without lupus nephritis.

BlossomHill Therapeutics (NASDAQ:BLSM) presented preclinical findings for BH-501284, an investigational pan-KRAS inhibitor, showing activity across KRAS-mutant cancer models.

Merck (NYSE:MRK) entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor being developed for potential cancer treatments.

SCYNEXIS (NASDAQ:SCYX) secured a contract with the Biomedical Advanced Research and Development Authority to support development of SCY-247, with potential funding of up to approximately $214 million.

Arvinas (NASDAQ:ARVN) dosed the first participant in a Phase 1/2 trial of ARV-6723, an investigational oral immuno-oncology candidate designed to degrade HPK1 in adults with advanced solid tumors.

Cosmos Health (NASDAQ:COSM) reported more than $20 million in implied revenue from Cana Laboratories’ contract manufacturing pipeline, based on management estimates over the expected duration of agreements.

AbbVie (NYSE:ABBV) received U.S. Food and Drug Administration approval for JUVMO (tavapadon) tablets to treat adults with Parkinson’s disease.

Biohaven (NYSE:BHVN) will present updated Phase 1 data for BHV-1530 at the EORTC-NCI-AACR oncology symposium in November 2026, covering the ongoing BHV1530-101 study.

Palatin Technologies (NASDAQ:PTN) reported fiscal 2026 collaboration and license revenue of $13.2 million, compared with zero revenue in fiscal 2025.

AN2 Therapeutics (NASDAQ:ANTX) received an extension of funding from the Gates Foundation to support its tuberculosis research collaboration with GSK focused on boron-based leucyl-tRNA synthetase inhibitors.